Market closed·Syncing…
Market closed · Close · 19 Nov

Dr. Lal Path Labs Ltd. LALPATHLABshare price and chart

Dr. Lal Path Labs closed at ₹1,963.20 on 19 November 2026, down 0.11% on the day. The 52-week range is ₹1,272.60 to ₹2,079.00.

₹1,963.20The price one share last traded at, in rupees.▼ 0.11% · ₹2.16
52-wk low ₹1,27386% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹2,079

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on LALPATHLAB

Real prices, every charge counted. Pick one or write your own.
What Dr. Lal Path Labs Ltd. does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Dr. Lal PathLabs runs independent diagnostic and pathology laboratories, 100% of its turnover, through 309 locations in India and three abroad, serving individual patients, hospitals, clinics, other healthcare providers and corporate clients.

1
1Sector

Healthcare Services

2
2What it sells

Diagnostic and pathology tests

3
3Who buys it

Patients, hospitals, clinics, corporates

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
51.4Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
61.1%Near average
today 61.1%20d avg 59.2%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+1.5%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+17.0%1 monthHow much the share price has changed over the period.+6.9%3 monthsHow much the share price has changed over the period.+4.0%1 yearHow much the share price has changed over the period.+24.9%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.28.4%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹32,952 Cr19 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.56.2xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.21.5%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.12.01xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.29.1%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.37.6xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.89%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.00xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.17.0%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Healthcare Service Provider · 15 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.56.19vs 34.87 median
Cheapest: ONEGLOBAL 11.99Priciest: VIJAYA 76.29
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.19.38%vs 12.68% median
Lowest: HEALTHX -1.41%Highest: 3BBLACKBIO 35.36%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.19.61%vs 25.84% median
Lowest: ONEGLOBAL -50.77%Highest: HEALTHX 60.66%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 4 Nov 2026), sales rose 19.6% from a year earlier to ₹874 cr and profit rose 27.4% to ₹194 cr.

Going well
  • Sales grew 3 years running (₹2,017 cr in FY23 to ₹2,763 cr in FY26).
  • Profit grew 3 years running (₹241 cr in FY23 to ₹510 cr in FY26).
  • Operating margin rose from 24.3% in FY23 to 28.3% in FY26.
  • Return on equity stayed above 15% from FY24 to FY26 (lowest 20.2%).
  • No borrowings at the FY26 balance sheet.
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
Also changed
  • Domestic institutions raised their holding by 3.7 points over 5 quarters (17.91% to 21.58%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 20 results, the share rose on 14 and fell on 6, and moved by 3% or more on 12.

+13%
-13%
Q2 FY23Q2 FY24Q2 FY25Q2 FY26Q2 FY27

Q2 FY27: results filed 4 Nov 2026. The share went from its close on 3 Nov 2026 to its close on 5 Nov 2026 +2.13%.

Dividend historyCash the company has paid per share, year by year.

₹890 / year
Paid 8 of 8 yrs
on ₹1 lakh at today's price · 0.89% yield · ₹17.5/share
What each year paid, on ₹1 lakh
242
306
509
306
153
764
637
891
19
20
21
22
23
24
25
26*
* 2026 so far - more may still be declared this year

2026 has paid ₹17.50 per share, about ₹891 on ₹1 lakh at today's price. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+12.7%a year, over 10 years
1 yr
+22.4%
3 yr
+13.3%
5 yr
+1.7%
10 yr
+12.7%

Held for 10 years this compounded at +12.7% a year. The last twelve months were up +22.4%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
52.93%promoter holding, as of 2026-09-30-2.3 pts since 2021
Promoter share since listing
2021-0952.93% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
52.9%
18.7%
21.6%
Promoter52.9%Foreign (FII)18.7%Domestic (DII)21.6%Public & others6.8%
Who is buying, who is leavingJun 25 to Sep 26
Promoter52.9%-0.9 pts
Foreign (FII)18.7%-2.9 pts
Domestic (DII)21.6%+3.7 pts

Each line is that holder's share of all shares over the last 7 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Insider tradesPurchases and sales of the company's own shares by promoters, directors and senior staff.

Last 18 months
Buy
Dr. Lal PathLabs Employees Welfare Trust
Other · 01-May-2026 16:15
82,750 sh
₹9.4 Cr
Sell
Rahul Sharma
Director · 31-Mar-2026 18:04
1,000 sh
₹13.0 L
Buy
Abhishek Aggarwal
Employees/Designated Employees · 24-Feb-2026 16:54
1,500 sh
₹15.4 L
Sell
Dr. Lal PathLabs Employees Welfare Trust
Other · 24-Feb-2026 16:54
2,024 sh
₹15.4 L
Sell
Dr. Lal PathLabs Employees Welfare Trust
Other · 19-Feb-2026 10:57
1,876 sh
₹6.7 L
Pledge
Jitender Sharma
Employees/Designated Employees · 11-Feb-2026 15:32
2,470 sh
₹35.7 L
Buy
Rahul Sharma
Director · 04-Feb-2026 18:07
4,000 sh
₹6.2 L
Sell
Rahul Sharma
Director · 31-Dec-2025 17:08
2,500 sh
₹36.6 L
Buy
Gaurav Sharma
Employees/Designated Employees · 31-Dec-2025 16:16
2,500 sh
₹25.4 L
Buy
Sanjay Kulshreshtha
Employees/Designated Employees · 31-Dec-2025 16:16
250 sh
₹2,500
Buy
Sanjay Kulshreshtha
Employees/Designated Employees · 31-Dec-2025 16:16
424 sh
₹2,120
Sell
Dr. Lal PathLabs Employees Welfare Trust
Other · 31-Dec-2025 16:16
4,424 sh
₹25.4 L
Sell
Abhishek Aggarwal
Employees/Designated Employees · 31-Dec-2025 16:16
1,750 sh
₹25.4 L
Buy
Ved Prakash Goel
Key Managerial Personnel · 17-Dec-2025 15:18
450 sh
₹4,500
Buy
Dr. Seema Narang Kochhar
Employees/Designated Employees · 17-Dec-2025 15:18
750 sh
₹7,500

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Copy of Newspaper Publication13-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication

Shareholders meeting12-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Notice of Postal Ballot

Analysts/Institutional Investor Meet/Con. Call Updates11-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange about Schedule of meet

Analysts/Institutional Investor Meet/Con. Call Updates10-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript

Copy of Newspaper Publication05-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication

Analysts/Institutional Investor Meet/Con. Call Updates04-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording

Press Release04-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated November 04, 2026, titled "Press Release on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2026".

Investor Presentation04-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation

Appointment04-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026.

General Updates04-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates

Record Date04-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of 2nd Interim Dividend is 11-Nov-2026.

Outcome of Board Meeting04-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026.

Dividend04-Nov-2026

Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on November 04, 2026, declared 2nd Interim Dividend of Rs. 5 per equity share.

Outcome of Board Meeting04-Nov-2026

Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Analysts/Institutional Investor Meet/Con. Call Updates27-Oct-2026

Dr. Lal Path Labs Ltd. has informed the Exchange about Schedule of meet

Backtest idea · LALPATHLABMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on LALPATHLAB
Backtest idea · LALPATHLABLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on LALPATHLAB
Backtest idea · LALPATHLABSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on LALPATHLAB
Your own ideaWrite a rule for LALPATHLAB in plain English“Buy LALPATHLAB when …”
Start writing
Buy the dip on LALPATHLABBuy when RSI(14) drops below 30
52-week high breakout on LALPATHLABBuy when closes at a 52-week high
Golden cross on LALPATHLABBuy when 50-day EMA crosses above 200-day
Stochastic oversold on LALPATHLABBuy when stochastic %K drops below 20
Pullback in an uptrend on LALPATHLABBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹32,952 cr
Largest of 15 peers
sector middle ₹867 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
56.2x
Higher than 90% of 10 peers
sector middle 34.9x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
12.0x
Higher than 85% of 13 peers
sector middle 4.4x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
21.5%
Higher than 88% of 8 peers
sector middle 13.6%
FY23 14.2%FY26 21.5%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
29.1%
Higher than 78% of 9 peers
sector middle 20.4%
FY23 19.7%FY26 29.1%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.00
No borrowings
sector middle 0.04
FY23 0.14FY26 0.00
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.9%
Higher than 93% of 15 peers
sector middle 0.0%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+19.6%
Lower than 67% of 9 peers
sector middle +25.8%
FY24 10.4%FY26 12.2%

Peers are the listed companies in the exchange's own industry group: Healthcare Service Provider. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.28.3%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.+27.4%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹2,763 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹510 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹18.5 as profit. Other income added ₹3.7.

Where it wentPer ₹100 of sales
Running costs₹71.7Depreciation₹5.9Interest₹0.8Tax₹5.8Profit₹18.5Other items₹1.1
Profit per ₹100, year by year
FY23FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+11.1%-+19.6%
Profit+28.4%-+27.4%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹50 Cr, after ₹167 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹636 Cr
Investing-₹422 Cr
Lenders and shareholders-₹264 Cr
Net change in cash-₹50 Cr
Operating cash per ₹100 of profit
₹189FY23₹148FY24₹116FY25₹125FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.·10.4%10.5%12.2%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.24.3%27.4%28.3%28.3%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.12.0%16.3%20.0%18.5%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.14.2%20.2%24.1%21.5%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.19.7%27.4%31.0%29.1%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.14x0.04x0.00x0.00x
Interest coverHow many times the company's profit before interest could pay its interest bill.10.2x18.2x29.0x30.3x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · LALPATHLABStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on LALPATHLAB
Backtest idea · LALPATHLABPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on LALPATHLAB
Backtest idea · LALPATHLABBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on LALPATHLAB
Backtest idea · LALPATHLAB52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on LALPATHLAB
Backtest idea · LALPATHLABGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on LALPATHLAB
MACD momentum on LALPATHLABBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on LALPATHLABBuy when closes below the lower Bollinger band
Supertrend rider on LALPATHLABBuy when supertrend turns up
Buy the dip on LALPATHLABBuy when RSI(14) drops below 30
52-week high breakout on LALPATHLABBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Healthcare Service Provider
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
LALPATHLAB
Dr. Lal Path Labs Ltd.
32,952 cr56.2x12.0x21.5%29.1%0.0019.4%+19.6%0.89%
VIJAYA
Vijaya Diagnostic Centre Limited
15,559 cr76.3x14.7x19.7%30.3%0.0022.4%+26.7%0.13%
METROPOLIS
Metropolis Healthcare Limited
11,587 cr51.6x7.1x13.4%19.6%0.0112.7%+15.8%0.36%
THYROCARE
Thyrocare Technologies Limited
8,035 cr56.1x14.5x28.7%37.8%0.0015.4%+25.1%1.39%
NEPHROPLUS
Nephrocare Health Services Limited
6,455 cr49.4x5.4x6.9%13.4%0.0711.5%-0.00%
SURAKSHA
Suraksha Diagnostic Limited
1,718 cr41.1x6.2x13.8%24.8%0.0211.9%+25.8%0.15%
KRSNAA
Krsnaa Diagnostics Limited
1,673 cr17.0x1.6x10.9%12.7%0.5711.1%+31.5%0.39%
3BBLACKBIO
3B Blackbio Dx Limited
1,130 cr19.1x----35.4%+42.4%0.38%
HEALTHX
Health X Platform Limited
867 cr-1.4x-0.2%-0.04-1.4%+60.7%0.00%
CREDENT
Credent Connect N Care Limited
860 cr-6.1x--0.15--0.00%
ONEGLOBAL
One Global Service Provider Limited
749 cr12.0x----14.1%-50.8%0.26%
GAUDIUMIVF
Gaudium IVF and Women Health Limited
724 cr28.7x4.4x16.1%20.4%0.0320.8%-0.00%
CHANDAN
Chandan Healthcare Limited
599 cr-3.5x-22.4%0.32--0.00%
PRAMODINI
Pramodini Medicare Limited
230 cr-2.0x--0.26--0.00%
INVICTA
Invicta Diagnostic Limited
97 cr-1.7x--0.02--0.00%
NIDAN
Nidan Laboratories and Healthcare Limited
18 cr14.8x0.3x-5.5%0.174.8%-8.4%0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-4.9
-0.7
-6.3
+4.2
+17.6
+2.0
+16.2
+1.5
+2.7
-4.1
+3.0
·
+32.4%
11m
2025
-4.9
-19.0
+7.3
+11.7
+0.6
+0.3
+12.7
+5.0
-5.8
+0.6
-2.7
-2.8
-1.2%
2024
-2.3
-6.6
-3.8
+4.8
+11.6
+5.0
+11.1
+10.6
-3.4
-5.7
-3.5
-0.1
+16.4%
2023
-7.0
-5.3
-8.1
+6.9
+4.0
+11.1
+3.0
-6.5
+16.0
-4.2
+11.5
-4.5
+14.0%
2022
-22.3
-15.3
+3.8
-0.4
-19.8
+3.6
+6.6
+11.4
-1.9
+1.8
-4.6
-7.6
-40.9%
2021
-2.5
+2.4
+17.7
+8.3
+0.8
+10.7
+8.7
+13.9
-9.3
-4.6
+8.0
+0.9
+65.8%
2020
+18.6
-8.1
-13.9
+13.1
-3.4
+2.1
+20.9
-6.2
+5.9
+22.2
-0.3
+0.6
+54.3%
2019
+18.5
-6.2
+3.3
+0.0
-0.6
+3.1
+1.7
+14.4
+11.9
+10.4
+2.0
-4.7
+64.1%
2018
+2.5
+0.9
-3.9
-3.7
+2.0
+11.2
-1.9
+11.3
-8.4
-8.2
-1.9
+5.5
+3.3%
2017
+4.2
-12.7
-0.6
-0.8
-5.8
-13.5
+6.7
-2.8
-1.6
-3.1
+15.2
-1.0
-17.7%
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2025-10-20GOLDMAN SACHS (SINGAPORE) PTE - ODI · blockSELL33,414₹3,160.00₹10.56 Cr
2025-10-20GOLDMAN SACHS BANK EUROPE SE - ODI · blockBUY33,414₹3,160.00₹10.56 Cr
2025-01-06MULTI-MANAGER ICVC · bulkSELL4,34,943₹2,997.11₹130.36 Cr
2022-10-03ISHARES CORE MSCI EMERGING MARKETS ETF · blockBUY45,068₹2,518.75₹11.35 Cr
2022-10-03ISHARES CORE EMERGING MARKETS MAURITIUS CO · blockSELL45,068₹2,518.75₹11.35 Cr
2022-10-03ISHARES INDIA SC MAURITIUS COMPANY · blockSELL8,417₹2,518.75₹2.12 Cr
2022-10-03ISHARES MSCI INDIA SMALL-CAP ETF · blockBUY8,417₹2,518.75₹2.12 Cr
2019-02-25TRUSTEES OF THE ESTATE OF BERNICE PAUAHI BISHOP DBA KAMEHAM · blockSELL1,27,666₹1,032.65₹13.18 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test LALPATHLAB. “Buy LALPATHLAB when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free